Byculla Homeopathic Pharmacy P Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-05-2024
- Paid Up Capital ₹ 0.10 M
as on 24-05-2024
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Revenue 0.77%
(FY 2020)
- Profit -10.53%
(FY 2020)
- Ebitda -9.39%
(FY 2020)
- Net Worth 5.51%
(FY 2020)
- Total Assets 5.50%
(FY 2020)
About Byculla Homeopathic Pharmacy P
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pharaoh Basta and Hufriz Basta serve as directors at the Company.
- CIN/LLPIN
U24239MH1994PTC078041
- Company No.
078041
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 1994
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Byculla Homeopathic Pharmacy P?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pharaoh Basta  | Director | 28-Apr-1994 | Current |
| Hufriz Basta | Director | 28-Apr-1994 | Current |
Financial Performance of Byculla Homeopathic Pharmacy P.
Byculla Homeopathic Pharmacy P Ltd, for the financial year ended 2020, experienced modest growth in revenue, with a 0.77% increase. The company also saw a substantial fall in profitability, with a 10.53% decrease in profit. The company's net worth moved up by a moderate rise of 5.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Byculla Homeopathic Pharmacy P?
In 2017, Byculla Homeopathic Pharmacy P had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Andheri Pharmaceuticals Pvt LtdActive 31 years 12 daysPharaoh Basta and Hufriz Basta are mutual person
- Ghatkopar Homeopathic Pharmacy P LtdActive 30 years 8 months
Pharaoh Basta and Hufriz Basta are mutual person
- Fort Homeo Pharmacy Private LimitedActive 30 years 8 months
Pharaoh Basta and Hufriz Basta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Byculla Homeopathic Pharmacy P?
Unlock and access historical data on people associated with Byculla Homeopathic Pharmacy P, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Byculla Homeopathic Pharmacy P, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Byculla Homeopathic Pharmacy P's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
